A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.

This time, her baby did test positive for SMA type 1, a severe neurodegenerative genetic condition that typically results in ...

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Urologists at Vanderbilt Health are enrolling men with stress urinary incontinence (SUI) in a clinical trial named SOPHIA2 to ...

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.

Live Science spoke with the scientists behind an upcoming clinical trial testing an immune therapy for depression.

Keenova Therapeutics plc announced the first-time publication of a retrospective analysis using previously generated XIAFLEX® (collagenase clostridium histolyticum) data. The analysis evaluates ...

It's been one month since Nancy Guthrie, the 84-year-old mother of NBC "Today" show host Savannah Guthrie, went missing from her Tucson-area home. Savannah Guthrie says the $1 million reward her ...